CHEK2 and cancer: Comparisons of individuals with biallelic variants in CHEK2 were made with WT (n = 33 034), as well as LR variant heterozygotes (n = 1566) or PV heterozygotes (n = 2167) for any cancer, multiple primary cancers, breast cancer, and bilateral breast cancer (Figure 2; Table).